Patents by Inventor Anyun MA

Anyun MA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF
    Publication number: 20230242613
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Application
    Filed: February 23, 2023
    Publication date: August 3, 2023
    Inventors: Yihong YAO, Jiaqi HUANG, Shigui ZHU, Wei ZHU, Xin YAO, Zhiyuan LI, Li ZHANG, Lin ZHU, Anyun MA, Yutian WEI, Yanfeng LI, Qingxia WANG, Jiaping HE
  • Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
    Patent number: 11618778
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: April 4, 2023
    Assignee: CELLULAR BIOMEDICINE GROUP INC.
    Inventors: Yihong Yao, Jiaqi Huang, Shigui Zhu, Wei Zhu, Xin Yao, Zhiyuan Li, Li Zhang, Lin Zhu, Anyun Ma, Yutian Wei, Yanfeng Li, Qingxia Wang, Jiaping He
  • Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
    Patent number: 11608369
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: March 21, 2023
    Assignee: Cellular Biomedicine Group, Inc.
    Inventors: Yihong Yao, Jiaqi Huang, Shigui Zhu, Wei Zhu, Xin Yao, Zhiyuan Li, Li Zhang, Lin Zhu, Anyun Ma, Yutian Wei, Yanfeng Li, Qingxia Wang, Jiaping He
  • CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF
    Publication number: 20220340640
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Application
    Filed: June 3, 2022
    Publication date: October 27, 2022
    Inventors: Yihong YAO, Jiaqi HUANG, Shigui ZHU, Wei ZHU, Xin YAO, Zhiyuan LI, Li ZHANG, Lin ZHU, Anyun MA, Yutian WEI, Yanfeng LI, Qingxia WANG, Jiaping HE
  • Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
    Patent number: 11472858
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: October 18, 2022
    Assignee: CELLULAR BIOMEDICINE GROUP HK LIMITED
    Inventors: Yihong Yao, Jiaqi Huang, Shigui Zhu, Wei Zhu, Xin Yao, Zhiyuan Li, Li Zhang, Lin Zhu, Anyun Ma, Yutian Wei, Yanfeng Li, Qingxia Wang, Jiaping He
  • CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF
    Publication number: 20220324940
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Application
    Filed: April 19, 2022
    Publication date: October 13, 2022
    Inventors: Yihong YAO, Jiaqi HUANG, Shigui ZHU, Wei ZHU, Xin YAO, Zhiyuan LI, Li ZHANG, Lin ZHU, Anyun MA, Yutian WEI, Yanfeng LI, Qingxia WANG, Jiaping HE
  • CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF
    Publication number: 20220281945
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 8, 2022
    Inventors: Yihong YAO, Jiaqi HUANG, Shigui ZHU, Wei ZHU, Xin YAO, Zhiyuan LI, Li ZHANG, Lin ZHU, Anyun MA, Yutian WEI, Yanfeng LI, Qingxia WANG, Jiaping HE
  • Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
    Patent number: 11339200
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: May 24, 2022
    Assignee: CELLULAR BIOMEDICINE GROUP HK LIMITED
    Inventors: Yihong Yao, Jiaqi Huang, Shigui Zhu, Wei Zhu, Xin Yao, Zhiyuan Li, Li Zhang, Lin Zhu, Anyun Ma, Yutian Wei, Yanfeng Li, Qingxia Wang, Jiaping He
  • CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF
    Publication number: 20210361710
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Application
    Filed: June 21, 2021
    Publication date: November 25, 2021
    Inventors: Yihong YAO, Jiaqi HUANG, Shigui ZHU, Wei ZHU, Xin YAO, Zhiyuan LI, Li ZHANG, Lin ZHU, Anyun MA, Yutian WEI, Yanfeng LI, Qingxia WANG, Jiaping HE
  • Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
    Patent number: 11066457
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: July 20, 2021
    Assignee: CELLULAR BIOMEDICINE GROUP HK LIMITED
    Inventors: Yihong Yao, Jiaqi Huang, Shigui Zhu, Wei Zhu, Xin Yao, Zhiyuan Li, Li Zhang, Lin Zhu, Anyun Ma, Yutian Wei, Yanfeng Li, Qingxia Wang, Jiaping He
  • ENGINEERED IMMUNE CELL CAPABLE OF INDUCING SECRETION OF ANTI-CD47 ANTIBODY
    Publication number: 20200255803
    Abstract: Provided are an immune cell capable of inducing the secretion of an anti-CD47 antibody when a CAR and/or an exogenous TCR is activated, a use thereof, and a preparation comprising the immune cell. Also provided are a preparation method of the immune cell and a kit for the preparation method.
    Type: Application
    Filed: September 27, 2018
    Publication date: August 13, 2020
    Inventors: Yongliang ZHANG, Liping LIU, Wei CAO, Ling MA, Anyun MA, Jiaping HE, Lianjun SHEN, Xinxin Wang
  • CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF
    Publication number: 20200002400
    Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
    Type: Application
    Filed: February 8, 2018
    Publication date: January 2, 2020
    Applicants: CELLULAR BIOMEDICINE GROUP (SHANGHAI) LTD., CELLULAR BIOMEDICINE GROUP (WUXI) LTD.
    Inventors: Yihong YAO, Jiaqi HUANG, Shigui ZHU, Wei ZHU, Xin YAO, Zhiyuan LI, Li ZHANG, Lin ZHU, Anyun MA, Yutian WEI, Yanfeng LI, Qingxia WANG, Jiaping HE